Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system

被引:118
作者
Schlicker, E
Morari, M
机构
[1] Univ Bonn, Dept Pharmacol & Toxicol, D-53113 Bonn, Germany
[2] Univ Ferrara, Pharmacol Sect, Dept Expt & Cli Med, I-44100 Ferrara, Italy
关键词
acetylcholine; glutamate; 5-hydroxytryptamine (serotonin; 5-HT); naloxone benzoylhydrazone; nociceptin; noradrenaline; Nphe(1)]nociceptin-(1-13)NH2; orphanin FQ; Phe(1)psi(CH2-NH)Gly(2)]nociceptin(1-13)NH2;
D O I
10.1016/S0196-9781(00)00233-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In this article, the effect of nociceptin (orphanin FQ) on transmitter release in the central nervous system in vitro and in vivo is reviewed. Nociceptin inhibits the electrically or K+-evoked noradrenaline, dopamine, serotonin, and glutamate release in brain slices from guinea-pig, rat, and mouse. This effect is usually naloxone-resistant but antagonized by OF, receptor antagonists like [Phe(1)psi(CH2-NH)Gly(2)]-nociceptin(1-13)NH2. In the rat in vivo, nociceptin diminishes acetylcholine release in the striatum: reduces dopamine release, and prevents the stimulatory effect of morphine on this transmitter in the nucleus accumbens and also elevates extracellular glutamate and gamma-aminobutyric acid levels in mesencephalic dopaminergic areas. The effect of nociceptin on the mesencephalic dopaminergic system might explain its actions on motor behavior. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1023 / 1029
页数:7
相关论文
共 61 条
  • [1] Interleukin-1 beta and tumor necrosis factor alpha inhibit the release of [H-3]-noradrenaline from isolated human atrial appendages
    Abadie, C
    Foucart, S
    Page, P
    Nadeau, R
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (03) : 384 - 389
  • [2] THE FUNCTIONAL-ANATOMY OF BASAL GANGLIA DISORDERS
    ALBIN, RL
    YOUNG, AB
    PENNEY, JB
    [J]. TRENDS IN NEUROSCIENCES, 1989, 12 (10) : 366 - 375
  • [3] The stereoselective κ-opioid receptor antagonist Mr2266 does not exhibit stereoselectivity as an antagonist at the orphan opioid (ORL1) receptor
    Bauer, U
    Nakazi, M
    Kathmann, M
    Göthert, M
    Schlicker, E
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (01) : 17 - 20
  • [4] A SYNAPTIC MODEL OF MEMORY - LONG-TERM POTENTIATION IN THE HIPPOCAMPUS
    BLISS, TVP
    COLLINGRIDGE, GL
    [J]. NATURE, 1993, 361 (6407) : 31 - 39
  • [5] Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay
    Calò, G
    Rizzi, A
    Marzola, G
    Guerrini, R
    Salvadori, S
    Beani, L
    Regoli, D
    Bianchi, C
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (02) : 373 - 378
  • [6] Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist
    Calo', G
    Guerrini, R
    Bigoni, R
    Rizzi, A
    Bianchi, C
    Regoli, D
    Salvadori, S
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3360 - 3366
  • [7] Characterization of [Nphe1]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist
    Calo', G
    Guerrini, R
    Bigoni, R
    Rizzi, A
    Marzola, G
    Okawa, H
    Bianchi, C
    Lambert, DG
    Salvadori, S
    Regoli, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2000, 129 (06) : 1183 - 1193
  • [8] CLARK JA, 1989, J PHARMACOL EXP THER, V251, P461
  • [9] Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ
    Devine, DP
    Taylor, L
    Reinscheid, RK
    Monsma, FJ
    Civelli, O
    Akil, H
    [J]. NEUROCHEMICAL RESEARCH, 1996, 21 (11) : 1387 - 1396
  • [10] DHAWAN BN, 1996, PHARMACOL REV, V48, P467